
Omeros (NASDAQ:OMER) reported higher third-quarter sales of its transplant complication treatment YARTEMLEA and a second consecutive quarter of positive operating cash flow, while a non-cash adjustment tied to its convertible notes pushed the company to a net loss.
YARTEMLEA generated $35.9 million in net sales during the third quarter of 2026, up 26% from $28.5 million in the second quarter. Gross sales rose 30% to $41.8 million. Chairman and CEO Greg Demopulos said revenue continued to grow in the fourth quarter, although the company did not provide a sales forecast.
The Food and Drug Administration approved YARTEMLEA in December 2025 for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, and Omeros launched it in late January. The company said the third quarter was the product’s second full quarter of sales.
Launch Expands Across Transplant Centers
As of September 30, 109 accounts had ordered YARTEMLEA, up from 73 at the end of June, Demopulos said. The company’s sales team is engaging all 175 U.S. transplant centers, he added.
Adult patients accounted for approximately 70% of utilization and pediatric patients 30%. Demopulos said that mix was moving toward the historical nationwide allogeneic transplant mix of 85% adult and 15% pediatric procedures.
Pharmacy and therapeutics committee approvals rose 25% during the quarter, and YARTEMLEA had approvals at 80% of the top 40 U.S. transplant centers by September 30, according to the company. Omeros also added 10 educational field positions, including a team of six nurse educators, to support awareness of TA-TMA and its treatment.
Gross-to-net deductions increased to 14% of gross sales from 11.5% in the second quarter, driven primarily by increased participation in the 340B drug pricing program. Management said that increase reflected growing outpatient use. Asked where the deductions might settle, Demopulos offered a tentative estimate in the high teens but said the company had not established a target.
Demopulos said Omeros expects to begin providing guidance at some point in 2027, once it has more data on sales and utilization.
Reimbursement and International Access
Management highlighted a Medicare new technology add-on payment that took effect October 1 and provides up to $287,000 in additional reimbursement per eligible inpatient case involving YARTEMLEA. Demopulos said many physicians and institutions were not widely aware of the award, making education a company priority.
He also said YARTEMLEA’s Medicare outpatient pass-through status runs through June 2029. That status exempts the drug from a reimbursement reduction for 340B-acquired drugs at affected hospitals beginning in 2027, the company said.
Outside the United States, Demopulos said the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion in October on the marketing authorization application for narsoplimab, YARTEMLEA’s active ingredient, after re-examination. He called the decision disappointing.
Omeros plans to close its compassionate-use program to new patients, citing increased U.S. commercial demand, while providing enough drug for current patients to complete treatment. The company is pursuing approvals in other countries and reimbursed named-patient programs in parts of Europe and other regions, Demopulos said.
Non-Cash Charge Drives Net Loss
Omeros posted a third-quarter net loss of $57.4 million, or 79 cents per share, compared with net income of $13.2 million, or 18 cents per share, in the second quarter. Chief Accounting Officer David Borges said the latest results included a $62 million non-cash mark-to-market loss on financial instruments associated with the company’s 2029 convertible notes.
Excluding non-cash remeasurements of embedded derivatives and other financial instruments, adjusted net income was $4.7 million, or 6 cents per share, up from $1.8 million, or 2 cents per share, in the prior quarter.
The company ended September with $95.3 million in cash and investments and generated $13.3 million in operating cash flow, compared with $4.1 million in the second quarter. Demopulos said he did not expect positive operating cash flow to change in the fourth quarter, though he declined to provide broader quarterly guidance.
In July, Omeros completed transactions to repurchase $30.5 million in principal of its 2029 convertible notes for $60.2 million plus accrued interest. The purchases reduced outstanding principal to $40.3 million. Borges said the company may opportunistically repurchase additional notes, depending on market conditions and other considerations.
Pipeline Plans
Omeros expects to begin two open-label, single-arm YARTEMLEA studies at the end of 2026 or early 2027, subject to approvals. One will evaluate the drug in hyperinflammatory acute respiratory distress syndrome; the other will test whether it can prevent TA-TMA in high-risk pediatric transplant patients. Each is designed to enroll approximately 50 to 60 patients.
Demopulos said the company is finalizing an initial phase 2 indication for OMS1029, its long-acting MASP-2 antibody. Omeros also expects to begin enrolling patients in an inpatient trial of OMS527 for cocaine use disorder in early 2027, following delays in obtaining animals for required non-clinical work. The company continues to expect clinical data in 2027.
For OMS805, an investigational acute myeloid leukemia treatment, Omeros is targeting a first-in-human trial in late 2027. Demopulos said the company does not plan regular updates on the program but expects to announce the start of the phase 1b trial and share clinical data when available.
About Omeros (NASDAQ:OMER)
Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.
